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EDITORIAL
RESEARCH
What makes an eLife paper in
epidemiology and global
health?
The best papers provide evidence that can be used to make
changes that improve the health and lives of people around
the world.
E
arlier this year an editorial explained what
eLife editors look for in a paper: ‘For us,
the ideal eLife paper presents an accu-
rate description of data that makes others in
the field think differently and moves the field
forward’ (Malhotra and Marder, 2015). Here
we outline how this applies to papers in
epidemiology and global health.
First, as with all manuscripts submitted to
eLife, we ask if the submission addresses an
important question and uses study designs
that provide a reasonably clear answer to that
question. The disciplines of epidemiology and
global health sit squarely on the boundary
between the natural, clinical and social
sciences, so a range of study designs can
be used. Experimental, observational and
theoretical lines of enquiry may all be
appropriate; both qualitative and quantitative
methods may also be used. Health and
disease are determined by a host of physical,
biological, psychological, technological,
social, economic and political factors, and
these factors need to be investigated both
individually and in combination. So eLife has
no pre-conceived notions of what constitutes
a good epidemiology or global health paper;
certainly we do not limit ourselves to experi-
mental studies or studies rooted in the natural
sciences alone. Indeed, we welcome the best
papers across the entire gamut of disciplines
that contribute to these fields, including those
that use rigorous scientific methods to explore
the impact of behavioural and socioeconomic
factors on health.
Second, research in epidemiology and
global health often directly informs decisions
at the hospital bedside or at the planning
office. Like the editors who handle submis-
sions in other areas of the life and biomedical
sciences, we seek submissions that represent
the best quality science in terms of rigor and
insight. However, researchers in epidemiology
and global health have an additional respon-
sibility to maximise the potential of their
work to save lives and improve health.
Hence we privilege submissions that have
the greatest potential impact on health
around the world, especially the health of
the worst off. This might be an analysis that
could lead to a new approach for cancer
care or malaria prevention that could save
millions of lives, or it could be the discovery
of a risk factor for an orphan disease which
we previously had little hope of preventing
or curing. This does not exclude methodolog-
ical papers that may not immediately save
lives but are highly likely to enable later
studies that do. We also welcome papers that
are so clear and persuasive in the way they
express important truths that they will be read
and re-read by clinicians and policy-makers.
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And since eLife is an open access journal, all
articles are freely available to everyone.
Third, we recognise that excellent science
can look different in epidemiology and global
health because studies are often less precise
and controllable than in many of the biological
sciences, let alone the physical sciences.
Preliminary findings often need to be corrob-
orated with larger, better controlled studies
and, eventually, the syntheses of many pieces
of relevant evidence. Hence we welcome
reports of high-quality clinical trials, along with
major reviews and meta-analyses that provide
the strength of evidence that will finally allow
the findings of smaller studies to be translated
into life-saving decisions. Ultimately, we ask
ourselves: does this manuscript constitute a
substantial step towards a clear answer to an
important global health question?
Much in epidemiology is of corroborative
value. Given the bluntness of our toolbox,
epidemiological findings must be replicated
before they can be considered as evidence for
the need to change practice in medicine and
public health. We respect that but believe that
papers that attempt to corroborate previous
findings without taking a substantial step forward,
or bringing a new angle to the problem, will
have a better home in specialty journals. We
seek to reward innovative and smart explorations
of population health data. Sometimes the intel-
lectual excitement that a paper elicits does not
come from the sophistication of the methodology
but from the clever use of simple methods to
reveal a possibly causal association that was
hidden from view in previous investigations.
Eureka moments exist in epidemiology; we wish
to display them prominently in eLife.
We recognise and celebrate the fact that
global health is now a truly international endeav-
our, and we are especially keen to receive
submissions from the low- and middle-income
nations that are under-represented in most
journals, including eLife. In the same vein, we
think it stands to reason that papers using new
data collected in these countries should normally
include co-authors from the countries whose
health-related data are the focus of the investiga-
tion. How else could these studies have captured
the appropriate context for an in-depth explora-
tion of the research problem?
In conclusion, when making decisions
about submissions in epidemiology and global
health, we look for all the things you would
expect to see in papers in a good journal—such
as a clear question, clever insights and clear
clarity of logic—combined with results and
findings that have the potential to improve
human health.
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